Skip to main content
Log in

TNFα Inhibitors in the Treatment of Psoriasis and Psoriatic Arthritis

  • Therapy Review
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Psoriasis is a chronic inflammatory skin disease that can lead to significant physical and psychologic distress for patients. Psoriatic arthritis (PsA), originally thought to be quite a mild disorder, is now recognized as a progressive and destructive arthritis. To date, therapies for both these conditions have been non-specific and unable to maintain long-lasting remission. In addition, many of the current therapies have significant adverse effects, limiting their usefulness. However, elucidation of the pathogenesis of psoriasis and PsA at a molecular level and the development of selective biologic agents have led to an enormous expansion of the armamentarium available to psoriasis patients.

Two agents (infliximab and etanercept) selectively block the role of the cytokine tumor necrosis factor (TNF)-α and have proved effective in clinical trials in the treatment of both the skin and the joint manifestations of psoriasis. A third anti-TNFα agent (adalimumab Humira®) is licensed for the treatment of rheumatoid arthritis; however, no studies have been published to date on its use in PsA or psoriasis. It is known that TNFα is elevated in both the skin and synovium of psoriatic patients and the effectiveness of its blockade by these two agents in psoriasis and PsA confirms its role in their pathogenesis.

Randomized, double-blind, placebo-controlled trials have been performed with both agents in the treatment of psoriasis and PsA; in the case of etanercept these have been to support US FDA approval for use in psoriatic arthropathy. These studies are supported by smaller cohorts in open-label studies and anecdotal reports in the literature. Anti-TNFα therapy has proved to have disease-reducing activity in PsA and psoriasis and appears to be well tolerated.

These studies have generally featured small numbers of patients and, until a larger cohort of treated patients is available, vigilance must be exercised. A considerable body of post-marketing safety data exists on the use of infliximab in rheumatoid arthritis and Crohn disease and for etanercept in rheumatoid arthritis and PsA. Certain issues, particularly the risk of infection, have emerged as features of the use of these agents. It remains to be seen whether effects seen in other disease entities may be extrapolated to psoriatic patients.

More long-term data and experience are needed to define the role of anti-TNFα agents in the management of psoriasis and PsA. In particular, more studies are required to elucidate the finer points of co-medication; in some studies both agents have been used with other medications but there have been no formal trials of various possible combinations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement

References

  1. Lebwohl M. Psoriasis. Lancet 2003; 361: 1197–204

    Article  PubMed  Google Scholar 

  2. Biondi Oriente C, Scarpa R, Pucino A, et al. Psoriasis and psoriatic arthritis. Acta Dermatol Venereol Suppl 1989; 146: 69–71

    Google Scholar 

  3. Burden AD. Identifying a gene for psoriasis on Chromosome 6 (Psor 1). Br J Dermatol 2000 Aug; 143(2): 238–41

    Article  PubMed  CAS  Google Scholar 

  4. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1–23

    Article  PubMed  Google Scholar 

  5. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis the new therapeutic frontier. Arch Dermatol 2002; 138: 657–63

    Article  PubMed  CAS  Google Scholar 

  6. Reish K, Mossner R, Konig IR, et al. Promoter polymorphisms of the genes encoding tumour necrosis factor-alpha and interleukin-lβ are associated with different subtypes of psoriasis characterised by early and late onset disease. J Invest Dermatol 2002 Jan; 118(1): 155–63

    Article  Google Scholar 

  7. Ettehadi P, Greaves MW, Wallach D, et al. Elevated tumour necrosis factor-alpha biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96: 146–51

    Article  PubMed  CAS  Google Scholar 

  8. Ackerman L, Harvima IT. Mast cells of psoriatic and atopic dermatitis skin are positive for TNF alpha and their degranulation is associated with expression of ICAM 1 in the epidermis. Arch Dermatol Res 1998; 290: 353–9

    Article  Google Scholar 

  9. Gladman DD, Stafford-Brady F, Chang C-H, et al. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990; 17: 809–12

    PubMed  CAS  Google Scholar 

  10. Mease PJ. Cytokine blockers in psoriatic arthritis. Ann Rheum Dis 2001; 60: iii37–40

    Google Scholar 

  11. Moll JMH, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3(1): 55–78

    Article  PubMed  CAS  Google Scholar 

  12. Partsch G, Steiner G, Leeb BF, et al. Highly increased levels of tumour necrosis factor-alpha and other pro-inflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24: 518–23

    PubMed  CAS  Google Scholar 

  13. Danning CL, Illei GG, Hitchon C, et al. Macrophage-derived cytokine and nuclear factor kB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 2000; 43: 1244–56

    Article  PubMed  CAS  Google Scholar 

  14. Ritchlin C, Haas-smith SA, Hicks D, et al. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998; 25: 1544–52

    PubMed  CAS  Google Scholar 

  15. Partsch G, Wagner E, Leeb BF, et al. Upregulation of cytokine receptors sTNF-R75 and sIL-2R in psoriatic arthritis synovial fluid. J Rheumatol 1998; 25: 105–10

    PubMed  CAS  Google Scholar 

  16. Van den Bosch F, Kruithof E, Baeten D, et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open label study. Ann Rheum Dis 2000 Jun; 59(6): 428–33

    Article  Google Scholar 

  17. Mease P. Psoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with etanercept. Clin Exp Rheumatol 2002 Nov–Dec; 20(6 Suppl. 28): S116–21

    PubMed  CAS  Google Scholar 

  18. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2002 Jun 9; 357(9271): 1842–7

    Article  Google Scholar 

  19. Gottlieb A, Masud S, Ramamurthi R, et al. Pharmacodynamic and pharmacokinetic response to anti-tumour necrosis factor-a monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 2003; 48: 68–75

    Article  PubMed  Google Scholar 

  20. Cauza E, Spark M, Cauza K, et al. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumour necrosis factor alpha inhibitor infliximab. Rheumatol Int 2002 Nov; 22(6): 227–32

    Article  PubMed  CAS  Google Scholar 

  21. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumour necrosis factor-alpha, infliximab. J Am Acad Dermatol 2002 Jun; 46(6): 886–91

    Article  PubMed  Google Scholar 

  22. Antoni C, Dechant C, Hann-Martin Lorenz PD, et al. Open label study of infliximab treatment: clinical and magnetic resonance imaging measurement of reduction of inflammation. Arthritis Rheum 2002 Oct 15; 47(5): 506–12

    Article  PubMed  CAS  Google Scholar 

  23. Ogilvie AL, Antoni C, Dechant C, et al. Treatment of psoriatic arthritis with anti tumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001 Mar; 144(3): 587–9

    Article  PubMed  CAS  Google Scholar 

  24. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumour necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000 May; 42 (Pt 1): 829–30

    Article  PubMed  CAS  Google Scholar 

  25. Tan MH, Gordon M, Lebwohl O, et al. Improvement of yoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumour necrosis factor alpha monoclonal antibody. Arch Dermatol 2001 Jul; 137(7): 930–3

    PubMed  CAS  Google Scholar 

  26. Newland MR, Weinstein A, Kerdel F. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol 2002 Jul; 41(7): 449–52

    Article  PubMed  CAS  Google Scholar 

  27. O’Quinn RP, Miller JL. The effectiveness of tumour necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of 2 cases. Arch Dermatol 2002 May; 138(5): 644–8

    Article  PubMed  Google Scholar 

  28. Kirby B, Marsland AM, Carmichael AJ, et al. Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin Exp Dermatol 2001 Jan; 26(1): 27–9

    Article  PubMed  CAS  Google Scholar 

  29. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385–90

    Article  PubMed  CAS  Google Scholar 

  30. Mease PJ. Etanercept, a TNF antagonist for treatment of psoriatic arthritis and psoriasis. Skin Therapy Lett 2003 Jan; 8(1): 1–4

    PubMed  CAS  Google Scholar 

  31. Gottlieb AB, Matheson RT, Lowe NJ, et al. Efficacy of etanercept in patients with psoriasis [abstract]. Ann Dermatol Venereol 2002; 129: 5280

    Google Scholar 

  32. Lebwohl M, Gottlieb A, Mease P, et al. Etanercept improves psoriasis activity in patients with psoriatic arthritis: results of a phase III multicentre trial [abstract p56 and poster]. 60th Annual Scientific Meeting of the American Academy of Dermatology; 2002 Feb 22-7; New Orleans

  33. Mease PJ, Goffe BS, Metz J, et al. Enbrel (etanercept) in patients with psoriasis and psoriatic arthritis [abstract 2019]. Arthritis Rheum 2000; 43(9 Suppl.): 403

    Google Scholar 

  34. Yazici Y, Erkan D, Lockshin MD. Etanercept in the treatment of severe, resistant psoriatic arthritis: one year follow-up [abstract POS-574]. Ann Rheum Dis 2000 Jul; 59 Suppl. 1: 198

    Google Scholar 

  35. Yazici Y, Erkan D, Lockshin MD. Etanercept in the treatment of severe, resistant psoriatic arthritis: continued efficacy and changing patterns of use after two years [letter]. Clin Exp Rheumatol 2002; 20(1): 115

    PubMed  CAS  Google Scholar 

  36. Iyer S, Yamanuchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 2002 Jan; 146(1): 118–21

    Article  PubMed  CAS  Google Scholar 

  37. El Kayam O, Yaron M, Caspi D. From wheels to feet: a dramatic response of severe chronic psoriatic arthritis to etanercept [letter]. Ann Rheum Dis 2000 Oct; 59(10): 839

    Article  Google Scholar 

  38. Cuellar ML, Mendez EA, Collins R, et al. Efficacy of etanercept in refractory arthritis (PsA) [abstract 235]. Arthritis Rheum 2000; 43: S106

    Google Scholar 

  39. Yazici Y, Erkan D, Lockshin MD. A preliminary study of etanercept in the treatment of severe resistant psoriatic arthritis. Clin Exp Rheumatol 2000 Nov–Dec; 18(6): 732–4

    PubMed  CAS  Google Scholar 

  40. Kamarashev J, Lor P, Forster A, et al. Generalised pustular psoriasis induced by cyclosporin withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept. Dermatology 2002; 205(2): 213–6

    Article  PubMed  CAS  Google Scholar 

  41. Van den Bosch F, Kruithof E, Baeten D, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 2002 Mar; 46(3): 755–65

    Article  Google Scholar 

  42. Baeten D, Kruithof E, Van den Dosch F, et al. Immunomodulatory effects of antitumour necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 2001 Jan; 44(1): 186–95

    Article  PubMed  CAS  Google Scholar 

  43. Van den Bosch F, Baeten D, Kruithof E, et al. Treatment of active spondylarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha. Ann Rheum Dis 2001; 60: iii33–36

    Google Scholar 

  44. Wanke LA, Gottlieb AB, Burge DJ, et al. Etanercept improves health related quality of life in patients with psoriatic arthritis [abstract PS31 and poster]. 60th Annual Scientific Meeting of the American Academy of Dermatology; 2002 Feb 22-7; New Orleans

  45. Hanauer SB. Safety of infliximab in clinical trials. Aliment Pharmacol Ther 1999 Sep; 13 Suppl. 4: 16–22

    Article  Google Scholar 

  46. Bazzoni F, Beutler B. The tumour necrosis factor ligand and receptor families. N Engl J Med 1996; 334: 1717–25

    Article  PubMed  CAS  Google Scholar 

  47. O’Dell JR. Anticytokine therapy: a new era in the treatment of rheumatoid arthritis? N Engl J Med 1999; 340: 310–2

    Article  PubMed  Google Scholar 

  48. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumour necrosis factor alpha-neutralising agent. N Engl J Med 2001; 345: 1098–104

    Article  PubMed  CAS  Google Scholar 

  49. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumour necrosis factor-alpha neutralising agent [letter]. N Engl J Med 2002; 346: 625–6

    Google Scholar 

  50. Slifman NR, Gershon SK, Lee JH, et al. Listeria monocytogenes infections as a complication of treatment with tumour necrosis factor alpha-neutralising agents. Arthritis Rheum 2003 Feb; 48(2): 319–24

    Article  PubMed  CAS  Google Scholar 

  51. Nunez Martinez O, Ripoll Noiseux C, Carneros Martin JA, et al. Reactivation tuberculosis in a patient with anti-TNF-alpha treatment [letter]. Am J Gastroenterol 2001; 96: 1665–6

    PubMed  CAS  Google Scholar 

  52. Morelli J, Wilson FA. Does administration of infliximab increase susceptibility to listeriosis? [letter]. Am J Gasroenterol 2000; 95: 841–2

    Article  CAS  Google Scholar 

  53. Kamath BM, Mamul P, Baldassano RN, et al. Listeria meningitis after treatment with infliximab. J Pediatr Gastroenterol Nutr 2002; 34: 410–2

    Article  PubMed  Google Scholar 

  54. Gluck T, Linde H-J, Scholmerich J, et al. Anti-tumour necrosis factor therapy and Listeria monocytogenes infection: report of two cases [letter]. Arthritis Rheum 2002; 46: 2255–7

    Article  PubMed  CAS  Google Scholar 

  55. Warris A, Bjornklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy [letter]. N Engl J Med 2001; 344: 1099–100

    Article  PubMed  CAS  Google Scholar 

  56. Singh SM, Rau N, Cohen LB, et al. Cutaneous nocardiosis complicating management of Crohn’s disease with infliximab and prednisone. CMAJ 2004 Oct 26; 171(9): 1063–4

    Article  PubMed  Google Scholar 

  57. Baghai M, Osmon DR, Wolk DM, et al. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 2001; 76: 653–6

    PubMed  CAS  Google Scholar 

  58. Chan ATY, Cleeve V, Daymond TJ. Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J 2002; 78: 47–8

    Article  PubMed  CAS  Google Scholar 

  59. Ritz MA, Jost R. Severe pneumococcal pneumonia following treatment with infliximab for Crohn’s disease [letter]. Inflamm Bowel Dis 2001; 7: 327

    Article  PubMed  CAS  Google Scholar 

  60. Keenan GF, Schaible TF, Boscia JA. Invasive pulmonary aspergillosis associated with infliximab therapy [reply]. N Engl J Med 2001; 344: 1100

    Google Scholar 

  61. Cohen RB, Dittirch KA. Anti-TNF therapy and malignancy: a critical review. Can J Gastroenterol 2001 Jun; 15(6): 376–84

    PubMed  CAS  Google Scholar 

  62. Brown SL, Green MH, Gershon SK, et al. Tumour necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002 Dec; 46(12): 3151–8

    Article  PubMed  CAS  Google Scholar 

  63. Antoni C, Braun J. Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol 2002; 20 Suppl. 28: S152–157

    Google Scholar 

  64. Van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activity in two multiple sclerosis patients treated with the monoclonal anti tumour necrosis factor antibody cA2. Neurology 1996; 47: 1531–4

    Article  Google Scholar 

  65. European Medicines Agency. Summary of product characteristics: Remicade® [online]. Available from URL: http://www.emea.eu.int/humandocs/PDFs/EPAR/Remicade/190199en4.pdf [Accessed 2003 Apr]

  66. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s Disease: a randomised controlled trial. Gastroenterology 2003; 124: 917–24

    Article  PubMed  CAS  Google Scholar 

  67. Moreland LW, Cohen SB, Baumgartner SW, et al. Long term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001; 28(6): 1238–44

    PubMed  CAS  Google Scholar 

  68. Fleischman R, Iqbal I, Nandeshwar P, et al. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. Drug Saf 2002; 25(3): 173–97

    Article  Google Scholar 

  69. Zeltser R, Tanck C, Holyst MM, et al. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumour necrosis factor alpha receptor. Fc fusion protein. Arch Dermatol 2001; 137:893–9

    PubMed  CAS  Google Scholar 

  70. Lovell DJ, Gianninni EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000; 136: 556–7

    Google Scholar 

  71. Skytta E, Pohjanoski H, Savolainen A. Etanercept and urticaria in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol 2000; 18: 533–4

    PubMed  CAS  Google Scholar 

  72. Galaria NA, Werth VP, Schumacher HR. Leukocytoclastic vasculitis due to etanercept. J Rheumatol 2000; 27: 2041–4

    PubMed  CAS  Google Scholar 

  73. Brion PH, Mittal-Henkle A, Kalunian KC. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis [letter]. Ann Intern Med 1999; 131: 634

    PubMed  CAS  Google Scholar 

  74. European Medicines Agency. Summary of product characteristics: Enbrel® [online]. Available from URL:http://www.emea.eu.int [Accessed 2003 Apr]

  75. Klareskog L, Moreland LM, Bohen SB, et al. Global safety and efficacy of up to five years of etanercept (Enbrel) therapy [abstract 150]. Arthritis Rheum 2001 Sep; 44 Suppl. 9: S77

    Google Scholar 

  76. Sabath DF, Holman J, Wallis WJ. Serious infection reports with etanercept (Enbrel) therapy [abstract OPOO00]. Ann Rheum Dis 2002; 61 Suppl. 1: 38

    Google Scholar 

  77. Fisher CJ, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumour necrosis factor receptor: Fc fusion protein. N Engl J Med 1996 Jun 27; 334(26): 1697–702

    Article  PubMed  CAS  Google Scholar 

  78. Philips K, Husni ME, Karlson EW, et al. Experience with etanercept in an academic medical centre: are infection rates increased? Arthritis Rheum 2002; 47: 17–21

    Article  Google Scholar 

  79. Aboulafia DM, Bundow D, Wilske K, et al. Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc 2000 Oct; 75(10): 1093–8

    Article  PubMed  CAS  Google Scholar 

  80. Mohan N, Edwards ET, Cupps TR, et al. Demyelination diagnosed during etanercept (TNF receptor fusion protein) therapy [abstract 970]. Arthritis Rheum 2000; 43: S228

    Google Scholar 

  81. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during antitumour necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44: 2862–9

    Article  PubMed  CAS  Google Scholar 

  82. Immunex. Enbrel (etanercept) prescribing information [online]. Available from URL:http://www.immunex.com [Accessed 2005 May]

  83. Shakoor N, Michalska M, Harris CA, et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359: 579–80

    Article  PubMed  CAS  Google Scholar 

  84. Blemuink GS, ter Borg EJ, Ramslaar CG, et al. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology 2001; 40: 1317–9

    Article  Google Scholar 

Download references

Acknowledgments

Dr B. Kirby is a paid consultant and in receipt of an unrestricted research grant from Serono International Incorporated (European distributor of efalizumab; another biologic treatment for psoriasis).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Brian Kirby.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tobin, AM., Kirby, B. TNFα Inhibitors in the Treatment of Psoriasis and Psoriatic Arthritis. BioDrugs 19, 47–57 (2005). https://doi.org/10.2165/00063030-200519010-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200519010-00006

Keywords

Navigation